Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Sales | 21,192 | 27,668 | 26,617 | 24,564 | 26,626 |
| Gross Profit | 21,192 | 27,668 | 26,617 | 24,564 | 26,626 |
| Operating Expenses | 33,602 | 36,396 | 38,243 | 35,870 | 34,695 |
| Operating Income | -12,410 | -8,728 | -11,626 | -11,306 | -8,069 |
| Other Income | 5,907 | -604 | -3,235 | -999 | -161 |
| Pre-tax Income | -6,503 | -9,332 | -14,861 | -12,305 | -8,230 |
| Income Tax | 427 | 298 | -229 | 18 | -439 |
| Net Income Continuous | -6,930 | -9,630 | -14,632 | -12,323 | -7,791 |
| Net Income | $-6,930 | $-9,630 | $-14,632 | $-12,323 | $-7,791 |
| EPS Basic Total Ops | -0.17 | -0.23 | -0.35 | -0.29 | -0.18 |
| EPS Basic Continuous Ops | -0.16 | -0.23 | -0.35 | -0.29 | -0.19 |
| EPS Diluted Total Ops | -0.17 | -0.23 | -0.35 | -0.29 | -0.18 |
| EPS Diluted Continuous Ops | -0.16 | -0.23 | -0.35 | -0.29 | -0.19 |
| EBITDA(a) | $-11,119 | $-7,462 | $-10,403 | $-10,145 | $-6,933 |